Uflex Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Earnings recovery underway, but uneven: Consolidated H1 EBITDA rose ~24% YoY, driven by a sharp BOPET margin recovery of over 200% in Q2, but BOPP gains have already reversed and overseas margins remain under pressure from Indian exports.
• The INR2,000 crores EBITDA target is "pretty much in sight": Management reaffirmed the full-year goal, citing new capacity, sustained BOPET strength, and easing lag effects, though unchanged Q3 overseas margins create a risk.
• Aseptic packaging is the structural growth story: Capacity is doubling to 2,400 crore packs, a new Egypt greenfield will serve a 500-crore-pack import market, and Q4 utilization is guided to ~83% post-expansion, implying 20% YoY volume growth.
• A capex-heavy balance sheet is creating a near-term P&L drag: PBT nearly halved QoQ as new project interest costs hit at 100% from day one while capacity ramps up gradually, a mismatch management acknowledges but cannot change under current accounting rules.
• What to watch next quarter: Whether BOPET margins hold their Q3 gains, the pace of new capacity ramp-up in Sanand and Mexico, and any progress on the long-promised offshore subsidiary listing.

Packaging Films: A Two-Speed Margin Recovery

• BOPET margins surged, then held: Industry-wide gross margins improved over 200% in Q2 vs Q1, driven by the full impact of June 15 price increases. Current-quarter margins are up a further ~20% over Q2, and management is "quite confident" H2 margins will remain at reasonable levels.
• BOPP gains evaporated: Gross margins rose 36% in Q2 over Q1, but a price correction in the current quarter has diminished all gains back to Q1 levels. Management hopes H2 margins return to Q2 levels, which "will be great for the industry."
• The export valve is self-correcting: BOPET exports from India fell ~10% QoQ and BOPP exports fell 5% because higher domestic prices made exports less attractive. More product staying home may pressure domestic margins, but then exports will rise again, a "continuing phenomenon."
• India's cost advantage is a double-edged sword: India is a much cheaper production jurisdiction than Europe or America, so when India had overcapacity, exports absorbed it. That improved domestic margins but kept overseas margins "under siege," a dynamic still playing out.
• Overseas capacity utilization is mixed: Poland PET fell to 68% from 78% in Q1, though past peak was ~100%. USA is running above 100% and Mexico at ~85% due to technical issues. Combined US-Mexico capacity is 8,000 tons/month but sales are 10,000 tons/month, requiring imports from Nigeria and India.
• Management declined to provide absolute BOPET margin numbers, offering only percentage increases when asked directly.

Rajesh Bhatia: "INR2000 crores is pretty much in sight."

Aseptic Packaging: The Structural Growth Engine

• Capacity doubling to 2,400 crore packs: Expansion from 1,200 crore packs is underway, with work over the next few years focused on absorbing and utilizing that capacity. Q4 utilization is guided to ~83% post-expansion, implying 20% YoY volume growth.
• Egypt greenfield targets an import-substitution market: Egypt consumes ~500 crore packs/year with no local producer, all imported. The new facility will serve Egypt, Africa, the Middle East, and Europe, with a treaty advantage for European exports. Customer qualifications are expected to be faster than Sanand because many export customers are already qualified.
• Egypt Aseptic EBITDA boost: At full capacity, the Egypt plant is expected to deliver 20% higher EBITDA over current consolidated levels.
• Liquor market optionality: Currently only three Indian states allow aseptic packaging for liquor. If all states permitted it, Uflex would need 3x its current India capacity just for that market.
• Seasonality is manageable: Q2 and Q3 are normally lean seasons for aseptic packaging, yet capacity utilization reached 93% in Q2 vs 83% last year.

Rajesh Bhatia: "We thought that Egypt is a good venue where we could set up this. It has a large market of its own. It doesn't have any facility. There's no producer currently."

Overseas Operations: Currency Drag and Margin Pressure

• Translation losses are large but notional: Nigeria, Mexico, and Egypt currencies continue devaluing vs INR, causing translation losses of ~₹92-93 crores in Q2, down from ₹180 crores in Q1. Management argues these are not real cash flow impacts: local balance sheets in Naira are fine, and actual losses would only crystallize if entities were disposed of.
• Overseas EBITDA declined QoQ: Overseas EBITDA fell to ₹223 crores from ₹240 crores in Q1, impacted by higher energy costs in Hungary during Q2, now normalized in the current quarter.
• No hedging strategy disclosed: When asked about hedging derivatives to reduce currency losses by 40-50%, management deflected, stating the losses are notional translation losses with no cash flow impact and that currency fluctuations are not in their control.
• US market is a bright spot: Management is "very upbeat" on US markets, noting the US is the second-largest market globally. A clear production gap exists: Uflex sells 2,000-2,500 tons more than it produces locally in the Americas, a deficit expected to grow to 3,000-3,500 tons in two years.

Rajesh Bhatia: "If I have to convert Naira's balance sheet into Rupee and Naira has depreciated for Rupee, then I will have to report those losses as per accounting standards. But when I look at my local balance sheets, when I do business in Naira, my balance sheets are fine, sir. I don't have any issue with that."

Capex Cycle: The P&L Mismatch

• New project interest costs hit P&L at 100% from day one: The PBT decline from ₹105 crores to ₹61.5-62 crores QoQ is driven by capital investments commissioned in March/April: a PET chips plant in India, a CPP facility in Russia, and other projects. Interest cost hits at full capacity utilization immediately, while actual capacity ramps up gradually.
• Finance cost rose from ₹162 crores to ₹177 crores QoQ: The increase reflects new project capitalization, higher local interest rates in Egypt and Nigeria, and a rising base SOFR rate on dollar borrowings in recent years.
• Three of four major projects complete this fiscal year: The Egypt PET facility, CPP facility in Mexico, and Sanand projects are all finishing in FY25. No other capex has been approved by the board beyond the Egypt aseptic expansion.
• PET chips plant is the next catalyst: Expected January to March, it will make Egypt, European, Nigeria, and UAE operations fully self-sufficient in PET chips raw material, with surplus for export to Mexico or the US. At full capacity, it is expected to boost normalized EBITDA of ₹2,000 crores by ~5%.
• Net debt rose ₹200 crores in the current fiscal due to pipeline projects. When asked about the high net debt of ₹5,900 crores and potential equity infusion, management acknowledged earlier attempts but cited bad market conditions for IPOs and did not commit to near-term equity raising in India.

Rajesh Bhatia: "The only difference is when you set up a project, complete a project, the interest cost comes and hits you on the day one on a 100% of the capacity while your capacity utilization only gradually goes up. So that mismatch will always be there unless the accounting policies allow that interest only to the extent of your capacity utilization levels should be taken into the P&L and the rest of the interest can be hidden in capital assets. But unfortunately, that is not the case."

Flexible Packaging: Steady State, Margin Lag

• A steady-state business with no growth ambitions: Volumes are ~20,000 tons/quarter with no surplus capacity and no plans to add capacity. Focus is on improving product mix toward pouching and increasing exports, where margins are better.
• Margin lag from Packaging Films price spikes: When Packaging Films prices rise steeply, Flexible Packaging margins contract because prices are fixed on previous month or quarter indexes. Increases come in subsequent periods per contract terms, creating a temporary squeeze.
• Domestic market is cutthroat: Large Indian customers are more price-sensitive than global counterparts, so the strategy is portfolio realignment toward value-added products and exports to improve the margin profile.
• Value-added coating lines are being installed in Mexico, Egypt, and Hungary to support the mix shift toward higher-margin products in FY26 and beyond.

Value Unlocking: Promises Without Timelines

• Offshore subsidiary listing is "low-hanging fruit": Management says listing the offshore subsidiary in Dubai or on the NYSE would attract 10x-12x enterprise valuations vs 4x-5x in India. The company was ready to file a prospectus with the NYSE but advisors said there was no point given unfavorable markets. No timeline was provided.
• No QIP in India until offshore listing reprices the stock: Management explicitly ruled out an Indian QIP, arguing India does not give the right valuations. Only after an offshore listing at higher multiples would India prices reflect revised valuations, at which point India could be considered.
• Restructuring into separate companies is a distant prospect: Management is considering separating commodity and value-added businesses, but this will "only emerge at a stage where the interdependence of the businesses are much lesser." No date was given.
• No non-core asset sales to reduce debt: When asked about selling non-core assets, management rejected the premise entirely, stating there are no such assets and the mindset is "all growth-oriented and revenue maximization and profit maximization."

Rajesh Bhatia: "We will not bring a QIP in India. Because India is not giving us the right value currencies... If I list my offshore company at 10x to 12x, then India's prices will obviously reflect those revised valuations. So, after that, we can consider India."

Guidance & Commitments

Key Metrics